Clinical Trial Update: First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy [Phase 2]

View source ↗

Summary

Ongoing Phase 2 trial evaluating first-line chemotherapy plus pembrolizumab, followed by pembrolizumab plus sacituzumab govitecan in extensive-stage small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Nir Peled | Conditions: NSCLC (non-small Cell Lung Cancer) | Phase 2 | Status: RECRUITING